☆ 4.7 Article

Elevated circulating level of β-aminoisobutyric acid (BAIBA) in heart failure patients with type 2 diabetes receiving sodium-glucose cotransporter 2 inhibitors

CARDIOVASCULAR DIABETOLOGY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Biochemistry & Molecular Biology

Differential effect of canagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, on slow and fast skeletal muscles from nondiabetic mice

Hiroko Otsuka et al.

BIOCHEMICAL JOURNAL (2022)

添加到收藏夹

Article Endocrinology & Metabolism

SGLT2 Inhibition Increases Fasting Glucagon but Does Not Restore the Counterregulatory Hormone Response to Hypoglycemia in Participants With Type 1 Diabetes

Schafer C. Boeder et al.

Summary: This study evaluated the effect of SGLT2 inhibitors on the glucagon response to hypoglycemia in individuals with type 1 diabetes. The results showed that although SGLT2 inhibitors increased basal glucagon concentrations, they did not restore the impaired glucagon response to hypoglycemia. Therefore, the reduction in hypoglycemia associated with SGLT2 inhibitors may be a result of changes in diabetes care rather than a direct physiological effect on alpha-cell function.

DIABETES (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Metabolic changes induced by dapagliflozin, an SGLT2 inhibitor, in Japanese patients with type 2 diabetes treated by oral anti-diabetic agents: A randomized, clinical trial

Kayo Horibe et al.

Summary: This study aimed to investigate the effects of the SGLT2 inhibitor dapagliflozin on body composition and amino acid metabolism. The results showed that dapagliflozin treatment significantly reduced body weight and fat mass, while maintaining fat-free mass. In addition, it also reduced intrahepatic triglyceride content. Changes in amino acids were minimal, with only a significant reduction in serine concentrations observed.

DIABETES RESEARCH AND CLINICAL PRACTICE (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

The SGLT2 inhibitor dapagliflozin promotes systemic FFA mobilization, enhances hepatic β-oxidation and increases ketosis

Kristina Wallenius et al.

JOURNAL OF LIPID RESEARCH (2022)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Direct cardiac effects of SGLT2 inhibitors

Sha Chen et al.

Summary: SGLT2 inhibitors have direct effects on cardiac cells, affecting ion balance, reducing inflammation and oxidative stress, regulating metabolism, and improving cardiac function. The unified explanation for these effects is the inhibition of sodium-loaders that affect the heart, especially under pathological conditions.

CARDIOVASCULAR DIABETOLOGY (2022)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects

Jason R. B. Dyck et al.

Summary: SGLT2 inhibitors have promising effects in treating heart failure patients. This review summarizes the cardiac effects of SGLT2i, including their impact on inflammation, oxidative stress, ion transport, and metabolism. These mechanisms play a crucial role in the development of heart failure.

JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2022)

添加到收藏夹

Review Endocrinology & Metabolism

Exerkines in health, resilience and disease

Lisa S. Chow et al.

Summary: This Review summarizes the importance and current state of exerkine research, highlighting the potential roles of exerkines in improving cardiovascular, metabolic, immune, and neurological health. Exerkines are signaling molecules released during exercise, which have the potential for the treatment of cardiovascular disease, type 2 diabetes mellitus, obesity, and to facilitate healthy aging.

NATURE REVIEWS ENDOCRINOLOGY (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis

Milton Packer

Summary: SGLT2 inhibitors promote cellular housekeeping and enhance cellular protection, leading to reduced progression of cardiomyopathy and nephropathy. Clinical studies suggest that SGLT2 inhibitors enhance nutrient deprivation signaling, resulting in a lower risk of heart failure and serious renal events.

CIRCULATION (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme

Faiez Zannad et al.

Summary: The study revealed that empagliflozin has significant effects on circulating protein levels in heart failure patients, potentially improving cardiovascular outcomes by promoting autophagic flux, nutrient deprivation signaling, and transmembrane sodium transport in the heart and kidneys.

EUROPEAN HEART JOURNAL (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of EMPEROR-Reduced

Gerasimos Filippatos et al.

Summary: This study investigated the efficacy and safety of Empagliflozin in HF patients of different age groups. The results showed that Empagliflozin consistently improved cardiovascular and renal outcomes across all age groups.

EUROPEAN JOURNAL OF HEART FAILURE (2022)

添加到收藏夹

Article Medicine, General & Internal

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

S. D. Solomon et al.

Summary: The study shows that SGLT2 inhibitors are effective in reducing the risk of hospitalization for heart failure and cardiovascular death among patients with chronic heart failure and a left ventricular ejection fraction of 40% or less. However, whether they are effective in patients with a higher left ventricular ejection fraction remains uncertain.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Review Medicine, General & Internal

Cardiorenal protection of SGLT2 inhibitors- Perspectives from metabolic reprogramming

Yue-Ming Gao et al.

Summary: SGLT2 inhibitors not only improve metabolic indicators but also protect the kidneys and heart, and these cardiorenal protective effects may be related to metabolic reprogramming.

EBIOMEDICINE (2022)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: Data from basic science and clinical trials

Lucia Scisciola et al.

Summary: Atherosclerosis is an inflammatory disease that leads to cardiovascular mortality and morbidity. Type 2 diabetes mellitus is a known risk factor for atherosclerosis. Sodium-glucose co-transporter 2 inhibitors have been found to have anti-inflammatory effects and can potentially slow down the progression of atherosclerosis.

FRONTIERS IN CARDIOVASCULAR MEDICINE (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Multi-omics insights into potential mechanism of SGLT2 inhibitors cardiovascular benefit in diabetic cardiomyopathy

Yangbo Xi et al.

Summary: Diabetic cardiomyopathy is a significant contributor to cardiovascular diseases, and SGLT2i has been shown to effectively reduce the risk of cardiovascular death and heart failure in patients with DCM. This study established a rat model of DCM and treated it with EMPA, and the metabolomic and proteomic analysis revealed potential targets and signaling pathways associated with the cardiovascular benefit of SGLT2i.

FRONTIERS IN CARDIOVASCULAR MEDICINE (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Plasma amino acid profiling improves predictive accuracy of adverse events in patients with heart failure

Hidemichi Kouzu et al.

Summary: The study retrospectively examined 301 patients with HF, finding that high concentrations of 3-methylhistidine and low concentrations of beta-alanine and valine were associated with adverse events. Plasma amino acid profiling improves risk stratification for HF patients.

ESC HEART FAILURE (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs

Dario Giugliano et al.

Summary: SGLT-2 inhibitors show a reduction in cardiovascular risk and renal efficacy in patients with cardiometabolic and renal diseases, leading to significant reductions in composite CV mortality or hospitalization for heart failure, heart failure, and renal outcomes.

CARDIOVASCULAR DIABETOLOGY (2021)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure

Shruti S. Joshi et al.

Summary: Patients with type 2 diabetes mellitus are at higher risk for heart failure, but SGLT2 inhibitor therapies show promise in improving blood glucose control and reducing cardiovascular events. However, the mechanisms underlying these benefits are not fully understood, with recent proposals pointing to improvements in cardiomyocyte calcium handling and reduction in epicardial fat as potential explanations.

HEART (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Effect of Dapagliflozin on Urine Metabolome in Patients with Type 2 Diabetes

Evdoxia Bletsa et al.

Summary: Dapagliflozin significantly alters urine metabolome in patients with type 2 diabetes in a glucose lowering-independent way. Most of the observed changes can be considered beneficial and may contribute to the renoprotective properties of dapagliflozin.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Epidemiology of Heart Failure A Contemporary Perspective

Veronique L. Roger

Summary: This review summarizes recent studies on the epidemiology of heart failure (HF) over the past decade, indicating that while the incidence of HF is mostly flat or declining, the burden of mortality and hospitalization remains significant, especially with major disparities among younger Black men and women. Emerging risk factors and holistic management approaches may help improve the treatment and management of HF.

CIRCULATION RESEARCH (2021)

添加到收藏夹

Review Endocrinology & Metabolism

Insulin action, type 2 diabetes, and branched-chain amino acids: A two-way street

Phillip J. White et al.

Summary: The association of obesity and insulin resistance with increased levels of branched-chain and aromatic amino acids and decreased glycine levels is well-established. Human metabolomics and genetic studies have further confirmed these observations, with preclinical studies identifying mechanisms involved in amino acid homeostasis disruption and its connection to dysregulated glucose and lipid metabolism, particularly in the development of insulin resistance, type 2 diabetes, and cardiovascular diseases.

MOLECULAR METABOLISM (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction EMPEROR-Preserved Trial

Milton Packer et al.

Summary: Empagliflozin significantly reduced the risk of heart failure-related inpatient and outpatient events in patients with heart failure with preserved ejection fraction, including cardiovascular death, heart failure hospitalization, and urgent visits, while also decreasing total heart failure hospitalizations and intensive care admissions. Patients receiving empagliflozin may experience improved New York Heart Association functional class levels.

CIRCULATION (2021)

添加到收藏夹

Article Medicine, General & Internal

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Stefan D. Anker et al.

Summary: Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases

Kai-Fan Tsai et al.

Summary: SGLT2 inhibitors not only lower glucose levels, but also have protective effects on the heart and kidneys in non-diabetic patients. They may also play a role in antioxidative effects in various human diseases such as liver diseases, neural disorders, and cancers, offering potential for novel therapeutic strategies.

ANTIOXIDANTS (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Plasma amino acid profiling improves predictive accuracy of adverse events in patients with heart failure

Hidemichi Kouzu et al.

Summary: This study suggests that plasma amino acid profiling can improve the prediction of clinical outcomes in HF patients, with high 3-methylhistidine and low beta-alanine concentrations independently associated with adverse events.

ESC HEART FAILURE (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Metabolic Profiling Associates with Disease Severity in Nonischemic Dilated Cardiomyopathy

Job A. J Verdonschot et al.

JOURNAL OF CARDIAC FAILURE (2020)

添加到收藏夹

Article Pharmacology & Pharmacy

Empagliflozin restores lowered exercise endurance capacity via the activation of skeletal muscle fatty acid oxidation in a murine model of heart failure

Hideo Nambu et al.

EUROPEAN JOURNAL OF PHARMACOLOGY (2020)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors JACC State-of-the-Art Review

Thomas A. Zelniker et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)

添加到收藏夹

Article Pharmacology & Pharmacy

β-Aminoisobutyric Acid Suppresses Atherosclerosis in Apolipoprotein E-Knockout Mice

Yuki Shimba et al.

BIOLOGICAL & PHARMACEUTICAL BULLETIN (2020)

添加到收藏夹

Review Endocrinology & Metabolism

Muscle-Organ Crosstalk: The Emerging Roles of Myokines

Mai Charlotte Krogh Severinsen et al.

ENDOCRINE REVIEWS (2020)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Omics phenotyping in heart failure: the next frontier

Antoni Bayes-Genis et al.

EUROPEAN HEART JOURNAL (2020)

添加到收藏夹

Article Endocrinology & Metabolism

Mechanisms of Sodium-Glucose Cotransporter 2 Inhibition: Insights From Large-Scale Proteomics

Ele Ferrannini et al.

DIABETES CARE (2020)

添加到收藏夹

Article Geriatrics & Gerontology

Overestimation of glomerular filtration rate by creatinine-based equation in heart failure patients is predicted by a novel scoring system

Tomoyuki Ishigo et al.

GERIATRICS & GERONTOLOGY INTERNATIONAL (2020)

添加到收藏夹

Article Medicine, General & Internal

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Milton Packer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Review Nutrition & Dietetics

Beta-Aminoisobutyric Acid as a Novel Regulator of Carbohydrate and Lipid Metabolism

Dmitrii A. Tanianskii et al.

NUTRIENTS (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

β-aminoisobutyric acid protects against vascular inflammation through PGC-1β-induced antioxidative properties

Miho Sawada et al.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2019)

添加到收藏夹

Article Medicine, General & Internal

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

J. J. V. McMurray et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Physiology

Acute Aerobic Exercise Leads to Increased Plasma Levels of R- and S-β-Aminoisobutyric Acid in Humans

Jan Stautemas et al.

FRONTIERS IN PHYSIOLOGY (2019)

添加到收藏夹

Article Pharmacology & Pharmacy

Empagliflozin, an SGLT2 Inhibitor, Reduced the Mortality Rate after Acute Myocardial Infarction with Modification of Cardiac Metabolomes and Antioxidants in Diabetic Rats

Hiroto Oshima et al.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2019)

添加到收藏夹

Review Endocrinology & Metabolism

A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans

Jack Alistair Sargeant et al.

ENDOCRINOLOGY AND METABOLISM (2019)

添加到收藏夹

Article Physiology

Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts

Masashi Mizuno et al.

PHYSIOLOGICAL REPORTS (2018)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Comparison of Propensity Score Methods and Covariate Adjustment Evaluation in 4 Cardiovascular Studies

Markus C. Elze et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)

添加到收藏夹

Article Nutrition & Dietetics

BAIBA Does Not Regulate UCP-3 Expression in Human Skeletal Muscle as a Response to Aerobic Exercise

Flor E. Morales et al.

JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION (2017)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Targeted Metabolomic Profiling of Plasma and Survival in Heart Failure Patients

David E. Lanfear et al.

JACC-HEART FAILURE (2017)

添加到收藏夹

Letter Cardiac & Cardiovascular Systems

Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease

Ben A. Kappel et al.

CIRCULATION (2017)

添加到收藏夹

Review Endocrinology & Metabolism

The mechanisms of action of metformin

Graham Rena et al.

DIABETOLOGIA (2017)

添加到收藏夹

Review Biochemistry & Molecular Biology

Amino acid profiling as a method of discovering biomarkers for early diagnosis of cancer

Edyta Siminska et al.

AMINO ACIDS (2016)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Piotr Ponikowski et al.

EUROPEAN HEART JOURNAL (2016)

添加到收藏夹

Article Endocrinology & Metabolism

BAIBA attenuates insulin resistance and inflammation induced by palmitate or a high fat diet via an AMPK-PPARδ-dependent pathway in mice

Tae Woo Jung et al.

DIABETOLOGIA (2015)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Metabolic Disturbances Identified in Plasma Are Associated With Outcomes in Patients With Heart Failure Diagnostic and Prognostic Value of Metabolomics

Mei-Ling Cheng et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2015)

添加到收藏夹

Article Cell Biology

β-Aminoisobutyric Acid Induces Browning of White Fat and Hepatic β-Oxidation and Is Inversely Correlated with Cardiometabolic Risk Factors

Lee D. Roberts et al.

CELL METABOLISM (2014)

添加到收藏夹

Article Medical Laboratory Technology

Improved separation and analysis of plasma amino acids by modification of the MassTrak™ AAA Solution Ultraperformance® liquid chromatography method

Roy W. A. Peake et al.

CLINICA CHIMICA ACTA (2013)

添加到收藏夹

Article Medical Laboratory Technology

Measurement of plasma amino acids by Ultraperformance® Liquid Chromatography

Srinivas B. Narayan et al.

CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2011)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.